Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Recently extracorporeal photopheresis (ECP), a new therapy involving extracorporeal activation of orally administered 8-methoxypsoralen (8-MOP), has been established for the treatment of different skin diseases. The pharmacokinetic profile of 8-MOP has been pursued in a clinical study which aimed to assess the efficacy of ECP in patients with progressive systemic sclerosis and cutaneous T-cell lymphoma. However, the enormous intraindividual variations in plasma as well as buffy coat concentrations affect the efficacy of oral 8-MOP therapy. Therefore, the introduction of a liquid 8-MOP formulation enabling the direct administration of the drug into the treatment bag of the ECP device is challenging.
Balogh
A
A
Institute of Clinical Pharmacology, Friedrich Schiller University, Jena, Germany.
Merkel
U
U
Looks
A
A
Vollandt
R
R
Wollina
U
U
D000328:Adult; D019540:Area Under Curve; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000628:therapy; D008297:Male; D008730:Methoxsalen / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D017893:Photopheresis; D017319:Photosensitizing Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000628:therapy
D017319:Photosensitizing Agents; D008730:Methoxsalen